Search
Aprepitant
go.drugbank.com/drugs/DB00673ApprovedInvestigationalAprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting … Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).
Categories: Aprepitant and Prodrugs, Alimentary Tract and MetabolismProducts: EMEND 125MG/80MG, APREPILOR 125MG/80MGMirococept
go.drugbank.com/drugs/DB06492ExperimentalMirococept (APT070) is a complement inhibitor currently under development for treatment of rheumatoid arthritis and I/RI. … It consists of the first three short consensus domains of human complement receptor 1 (CR1), manufactured in recombinant bacteria and modified with a membrane-targeting amphiphilic peptide based on the
Tenapanor
go.drugbank.com/drugs/DB11761ApprovedInvestigational[A185492] As an inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3) transporter, it is the first and currently only medication within its class[A185489,A185492,A185495] and therefore exists as … [L8558] It was first designed and synthesized in 2012.
Categories: Alimentary Tract and MetabolismTM30339
go.drugbank.com/drugs/DB05085ExperimentalTM30339 is an analogue of the natural hormone Pancreatic Polypeptide (PP), which is released in connection with meals. … TM30339 works through the same receptor as the natural satiety hormone, Pancreatic Polypeptide (PP), but TM30339 has improved properties compared with PP.
MBO7133
go.drugbank.com/drugs/DB04999ExperimentalMB07133 is a HepDirect prodrug of an activated form of cytarabine (araC), an anti-cancer drug that is used to treat leukemia but is ineffective against primary liver cancer. … Higher doses of araC cannot be used to overcome this limitation due to bone marrow toxicity resulting from rapid activation in that tissue.
Dexmethylphenidate
go.drugbank.com/drugs/DB06701ApprovedInvestigationalDexmethylphenidate is the dextrorotary form of methylphenidate introduced in 2002[A177181]. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant[A177193].
Categories: Methylphenidate and isomer, dexmethylphenidate and serdexmethylphenidateSevabertinib
go.drugbank.com/drugs/DB21667ApprovedInvestigational[L54638] Sevabertinib was granted accelerated approval by the FDA on November 19th, 2025 for patients who had received a prior systemic therapy.
Categories: MATE 2-K InhibitorsHydrocortamate
go.drugbank.com/drugs/DB00769ApprovedGlucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic
Zolazepam
go.drugbank.com/drugs/DB11555ExperimentalVet approvedIt is around four times the potency of diazepam but it is both water-soluble and un-ionized at physiological pH meaning that its onset is very fast. … Zolazepam is a pyrazolodiazepinone derivative used as an anaesthetic in veterinary medicine.